Takeda to integrate its Ireland subsidiaries

Takeda Pharmaceutical Company has reported that it will integrate its wholly owned subsidiaries Takeda Ireland Limited or TIL and Takeda Pharma Ireland Limited or TPI into a single operation on July 1, 2009, through a complete transfer of TPI’s assets to TIL. TPI will be liquidated following the completion of assets transfer and other necessary formalities.

TIL has manufactured drug formulation for the European and North American markets, starting with the anti-hypertension treatment Blopress in 1999 and expanding to the anti-diabetic treatment Actos and the peptic ulcer treatment Prevacid. TPI has operated as an active pharmaceutical ingredient – (API) manufacturing center since 2007, handling the ingredients of the insomnia treatment Rozerem. 

Takeda has decided to integrate its two Irish operations so as to enhance productivity as it continues to globalize its operations to become a world-class pharmaceutical company.

Takashi Inkyo, general manager of pharmaceutical production division at Takeda, said: The new company realized through the integration of the two Irish plants will allow for increased efficiency in support functions, greater productivity and reduced costs, thanks to an integrated production management system that covers all processes, from API to drug formulation. Takeda intends to further promote productivity in all its manufacturing centers around the world, as we realize an enhanced global production system.